Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...

Your Monthly Dose of Good News: - 300,000 landmines removed in Sri Lanka - Mexico enacts new law to protect sharks - North ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...

Its growth is supported by the anticipated launch of 26 new pipeline agents. The age-related macular degeneration (AMD) ...